Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
08:00am, Wednesday, 10'th Apr 2024
SAN RAFAEL, Calif. , April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a con
Miracle growth: Discover the biotech stock behind decades of jaw-dropping returns
07:11am, Friday, 15'th Mar 2024
Although many popular biotech stocks peaked in 2020 and early 2021 and then started to decline, early 2024 has seen signs of recovery and a return of investors' trust. Nonetheless, this biotech stock
Investigator-Sponsored Phase 2 Study Demonstrated Positive Results for VOXZOGO in Children with Hypochondroplasia New Analyses Highlight VOXZOGO 7-year Data and Improvement on Quality of Life in Child
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
08:30am, Thursday, 07'th Mar 2024
Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif. , March 7, 2024 /PRNewswire/ -- BioMarin
BioMarin Scheduled to Participate in March Investor Conferences
09:00am, Friday, 01'st Mar 2024
- Cowen 44th Annual Healthcare Conference on March 5 - Leerink Partners Global Biopharma Conference on March 11 - Jefferies Biotech on the Bay Summit on March 12 -�
BioMarin Pharma gets DOJ subpoena on certain drug testing programs
02:14pm, Monday, 26'th Feb 2024
BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, it said in a filing on
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
12:35pm, Friday, 23'rd Feb 2024
BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.
BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript
09:08pm, Thursday, 22'nd Feb 2024
BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings
07:01pm, Thursday, 22'nd Feb 2024
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Str
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
06:16pm, Thursday, 22'nd Feb 2024
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.36 per share a year ago.
5 Stocks Likely to Gain on Q4 Earnings Today After Market Close
08:11am, Thursday, 22'nd Feb 2024
We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are: BKNG, AMH, FND, BMRN, PBA.
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
10:16am, Wednesday, 21'st Feb 2024
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
11:06am, Thursday, 15'th Feb 2024
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
06:46am, Thursday, 15'th Feb 2024
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
7 Biotech Stocks Fighting America's Deadliest Diseases
04:10pm, Thursday, 08'th Feb 2024
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
